OptiNose — Q3 2019 Earnings Presentation
17 slides from OptiNose's earnings presentation, Nov 12, 2019
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 12, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Q3 2019 Key Highlights
Q3 2019 Key Highlights XHANCE Q3 2019 TRx Growth of 27% compared to Q2 2019, and 18% growth in October 2019 compared to September 2019 • TRx growth supported by increases in both NRx and refill rate in Q3 2019 XHANCE Average Net Revenue per Prescription • $202 in Q3 2019 and $194 for September YTD 2
Slide 4: XHANCE Launch Update
-XHANCE Launch Update optinose_
Slide 5: XHANCE Prescription Volume Grew 27% in Q3 versus Q2 2019
XHANCE Prescription Volume Grew 27% in Q3 versus Q2 2019 and 18% in October versus September 2019 Strong growth in both new prescriptions and refills drove XHANCE quarterly prescription growth of 27% in Q3 2019 XHANCE TRx (in thousands) XHANCE TRx (in thousands) +27% 50 25 +51% +18% vs 45 43.0 Sept
Slide 6: XHANCE Share of INS Prescriptions Within Target Physician Audience is Growing
XHANCE Share of INS Prescriptions Within the Target Physician Audience is Growing and the Remaining Opportunity is Large Market share within the XHANCE target physician audience has increased consistently in 2019 and that trend continues in early Q4 2019 XHANCE Share of INS TRx Within Target Physici
Slide 7: Additional Commercial Updates
Additional Commercial Updates DTC Test Market Pilot nearing completion ▪ Full analysis at the end of the pilot is expected to drive decisions regarding a potential DTC program in 2020 XHANCE Target Physician Perception Survey ▪ We are encouraged by the continued progress we see in our market researc
Slide 8: Q3 2019 Financial Update
Q3 2019 Financial Update
Slide 9: Pharmakon Debt Financing Expected to Extend Cash Runway
Pharmakon Debt Financing Expected to Extend Cash Runway $125 million of cash on the balance sheet as of 9/30/2019 Financing is expected to provide incremental cash of up to $70 million total through 2021† $30 million expected to be drawn in early 2020 based $ on anticipated FY 2019 XHANCE Net Revenu
Slide 10: Financial Review – Third Quarter 2019
Financial Review – Third Quarter 2019 Q3 2019 XHANCE Net Revenue Increased 30% to $8.7 Million ($M ) XHANCE Net Revenue Average Net Revenue per TRx $19.3M $8.7 ▪ Average XHANCE net YTD 2019 revenue of $202 per TRx in $6.7 Q3 2019 – Increased from $197 in Q2 $4.0 2019 $3.0 ▪ $1.9 Average XHANCE net r
Slide 11: Updated 2019 Financial Guidance
Updated 2019 Financial Guidance ▪ 2019 XHANCE Net Revenue expected to be $30 - $33 million ▪ Prior guidance range was $29 - $34 million ▪ 2019 XHANCE Average Net Revenue per Prescription expected to be $195 - $205 ▪ Prior guidance range was $185 to $205 ▪ 2019 Operating Expenses (GAAP) expected to b
Slide 12: Pipeline Update
\ Pipeline Update optinose_
Slide 13: XHANCE Chronic Sinusitis Indication (sNDA)
XHANCE Chronic Sinusitis Indication (sNDA) The Chronic Sinusitis development program includes two Phase 3b clinical trials that are 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter studies • Top line results expected in second half 2021 Study 3205 • Estimated enrollm
Slide 14: Closing Remarks
Closing Remarks optinose_
Slide 15: Key Takeaways
Key Takeaways Commercial Strategy Driving Strong XHANCE Growth Substantial Growth Opportunity Remains for XHANCE Maintaining/Improving on all Financial Guidance Measures Strong Balance Sheet - Pharmakon Provides Access to Additional Cash Successfully completing other important corporate objectives +
Slide 16: Investor Relations
Investor Relations – NASDAQ: OPTN 1 At 30 September 2019: Analyst Coverage – $125 million in cash – Long-term debt: $80 million BMO: Gary Nachman – 41.5 million common shares o/s – 10.4 million options & warrants o/s Jefferies: David Steinberg Cantor Fitzgerald: Brandon Folkes Optinose Investor Cont
Slide 17: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation November 12, 2019